- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Partnership with MD Anderson
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, announced that it has issued an update note on DelMar Pharmaceuticals (OTCQX:DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, announced that it has issued an update note on DelMar Pharmaceuticals (OTCQX:DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
SeeThruEquity CEO, Ajay Tandon, stated:
Since our last update on the company, Delmar has announced a major new collaborative partnership with the University of Texas MD Anderson Cancer Center. In our view, the announcement underscores the progress Delmar has made in showing that VAL-083 has potential to significantly improve the standard of care for GBM, and the management has stated that it believes the small molecule may offer measurable “advantages over currently available chemotherapies in a number of tumor types.
In the announcement, Delmar indicated that MD Anderson had agreed to “extend and accelerate” the clinical development of VAL-083 for glioblastoma multiforme patients following first recurrence of the disease. As part of the collaboration, MD Anderson has agreed to initiate a new Phase II clinical study with VAL-083 at first recurrence/progression, prior to Avastin® exposure. Eligible patients will have recurrent GBM characterized by a high expression of MGMT, the DNA repair enzyme implicated in drug-resistance and poor patient outcomes following current front-line chemotherapy.We are reiterating our price target of $5.75 per share.
Connect with DelMar Pharmaceuticals (OTCQX:DMPI) to receive an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.